Aveo Pharmaceuticals (AVEO) 1.21 $AVEO
Top Gainers Technical Data -- Research on Northwest Biotherapeutics, Midstates Petroleum, AVEO Pharma, and Infinity Pharma
PR Newswire - Mon May 12, 7:21AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Midstates Petroleum Company Inc. (NYSE: MPO), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free technical research on NWBO, MPO, AVEO and INFI can be downloaded upon signing up at:
Narrower-than-Expected Loss at AVEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2014 loss of 5 cents per share (excluding one-time expenses).
AVEO Oncology Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
AVEO Oncology to Report First Quarter 2014 Financial Results on May 7, 2014
Business Wire - Mon May 05, 7:36AM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014.
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
AVEO-Biodesix Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:00PM CDT
AVEO Pharma entered into an agreement with Biodesix to develop and commercialize ficlatuzumab with VeriStrat.
AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Business Wire - Thu Apr 10, 5:30AM CDT
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix(R) companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat(R), a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). VeriStrat will be used as the selection assay to identify NSCLC patients most likely to benefit from ficlatuzumab.
Technical Pointers on Top Gainers -- Research on Newfield Exploration, Endocyte, Columbia Property Trust, and AVEO Pharma
PR Newswire - Mon Mar 24, 9:09AM CDT
The US markets saw mixed sentiments on Friday, March 21, 2014, with the NASDAQ Composite closing at 4,276.79, down 0.98%, the Dow Jones Industrial Average ending the session at 16,302.77, down 0.17% and the S&P 500 edging 0.29% lower to finish the trading session at 1,866.52. During the session, gains in the Energy, Utilities, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Discretionary, Information Technology, and Health Care sectors. A number of stocks saw large movements, including Newfield Exploration Co. (NYSE: NFX), Endocyte Inc. (NASDAQ: ECYT), Columbia Property Trust Inc. (NYSE: CXP) and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Free technical research on NFX, ECYT, CXP and AVEO can be downloaded upon signing up at:
AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 8:39AM CDT
AVEO Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 7% on the day.
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
Business Wire - Thu Mar 13, 2:22PM CDT
--- Focuses internal R&D investment on AV-380 in cachexia -
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Business Wire - Fri Feb 14, 4:30AM CST
--AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Top Gainers Technical Data -- Research on Northwest Biotherapeutics, Midstates Petroleum, AVEO Pharma, and Infinity Pharma
PR Newswire - Mon May 12, 7:21AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Midstates Petroleum Company Inc. (NYSE: MPO), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free technical research on NWBO, MPO, AVEO and INFI can be downloaded upon signing up at:
Narrower-than-Expected Loss at AVEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2014 loss of 5 cents per share (excluding one-time expenses).
AVEO Oncology Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
AVEO Oncology to Report First Quarter 2014 Financial Results on May 7, 2014
Business Wire - Mon May 05, 7:36AM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014.
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
AVEO-Biodesix Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:00PM CDT
AVEO Pharma entered into an agreement with Biodesix to develop and commercialize ficlatuzumab with VeriStrat.
AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Business Wire - Thu Apr 10, 5:30AM CDT
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix(R) companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat(R), a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). VeriStrat will be used as the selection assay to identify NSCLC patients most likely to benefit from ficlatuzumab.
Technical Pointers on Top Gainers -- Research on Newfield Exploration, Endocyte, Columbia Property Trust, and AVEO Pharma
PR Newswire - Mon Mar 24, 9:09AM CDT
The US markets saw mixed sentiments on Friday, March 21, 2014, with the NASDAQ Composite closing at 4,276.79, down 0.98%, the Dow Jones Industrial Average ending the session at 16,302.77, down 0.17% and the S&P 500 edging 0.29% lower to finish the trading session at 1,866.52. During the session, gains in the Energy, Utilities, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Discretionary, Information Technology, and Health Care sectors. A number of stocks saw large movements, including Newfield Exploration Co. (NYSE: NFX), Endocyte Inc. (NASDAQ: ECYT), Columbia Property Trust Inc. (NYSE: CXP) and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Free technical research on NFX, ECYT, CXP and AVEO can be downloaded upon signing up at:
AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 8:39AM CDT
AVEO Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 7% on the day.
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
Business Wire - Thu Mar 13, 2:22PM CDT
--- Focuses internal R&D investment on AV-380 in cachexia -
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Business Wire - Fri Feb 14, 4:30AM CST
--AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
